Tamibarotene + Azacitidine + Daratumumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Trial Timeline
Sep 20, 2016 → Jan 25, 2023
NCT ID
NCT02807558About Tamibarotene + Azacitidine + Daratumumab
Tamibarotene + Azacitidine + Daratumumab is a phase 2 stage product being developed by Syros Pharmaceuticals for Acute Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02807558. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02807558 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia